4basebio AG: 4basebio reports on results of the Extraordinary General Meeting 2021

Heidelberg (pta034/28.01.2021/17:15 UTC+1) 4basebio AG (Frankfurt: 4BSB; ISIN: DE000A2YN801; Prime Standard) announces the results of its extraordinary general meeting today. The shareholders of the Company have approved all proposed resolutions of the Management Board and the Supervisory Board, which were published in the Federal Gazette on 05 January 2021, with a large majority.

The Company held today's Extraordinary General Meeting as a virtual event without the physical presence of shareholders and their proxies (online EGM), as allowed by the German legislator in view of the Corona pandemic. Registered shareholders were able to exercise their voting rights before and during the AGM by postal vote or by proxy to the Company's proxy. Questions could be submitted up to two days before the event or asked verbally or in writing during the general debate. The Annual General Meeting could be followed online in sound and vision by registered shareholders.

Further information on the Extraordinary General Meeting including the detailed voting results as well as the Management Board presentation will be published after the event on the 4basebio AG Extraordinary General Meeting 2021 page at: https://investors.4basebio.com/de/ausserordentliche-hauptversammlung-2021/

About 4basebio AG:
4basebio AG is a company listed in the PRIME Standard of the Frankfurt Stock Exchange which acquires, holds, manages and sells investments in corporations and partnerships, in particular - but not exclusively - in the biotechnology, life science and IT sectors in Germany and abroad.
Global investments or investments in unlisted companies or financial instruments are also possible. This is done according to the best risk-reward profile. The focus is on long-term capital preservation and a positive overall return. The company is listed in the Prime Standard of the Frankfurt Stock Exchange (ticker: 4BSB; ISIN: DE000A2YN801).

More information: www.4basebioag.com
***
For further information please contact:

4basebio AG
Dr Robert Mayer, Manager IR
Tel: +49 171 3876540
Email: r.mayer@4basebioag.com

### This publication is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Certain statements contained in this press release that do not relate to proven financial results or other historical data should be considered forward-looking, meaning that such statements are primarily predictions of future results, trends, plans or objectives. These statements should not be considered as total guarantees because, by their nature, they are subject to known and unknown risks and uncertainties and may be affected by other factors that could cause 4basebio AG's actual results, plans and objectives to differ materially from any stated conclusions or implied predictions contained in such statements. 4basebio undertakes no obligation to publicly update or revise any of these statements, whether as a result of new information, future results or otherwise. ##

(end)

Emitter:	4basebio AG Waldhofer Str. 102 69123 Heidelberg Germany
Contact Person:	Robert Mayer
Phone:	+49 171 3876540
E-Mail:	robert.mayer@4basebio.com
Website:	investors.4basebio.com
ISIN(s):	DE000A2YN801 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate